JENBURPHPharmaceuticals
Jenburkt Pharmaceuticals Ltd — Cash Flow Statement
₹955.45
+0.34%
Jenburkt Pharmaceuticals Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 8.19 Cr | 5.57 Cr | 14.95 Cr | 6.22 Cr | — |
| Capital Expenditure | -19.71 Cr | -2.55 Cr | -2.10 Cr | -3.05 Cr | — |
| End Cash Position | 7.36 Cr | 4.13 Cr | 3.66 Cr | 5.03 Cr | — |
| Beginning Cash Position | 4.13 Cr | 3.66 Cr | 5.03 Cr | 2.49 Cr | — |
| Changes In Cash | 3.24 Cr | 0.47 Cr | -1.37 Cr | 2.54 Cr | — |
| Financing Cash Flow | -7.62 Cr | -7.08 Cr | -21.04 Cr | -5.53 Cr | — |
| Interest Paid Cff | -0.28 Cr | -0.25 Cr | -0.52 Cr | -0.34 Cr | — |
| Cash Dividends Paid | -6.78 Cr | -6.32 Cr | -5.50 Cr | -4.68 Cr | — |
| Investing Cash Flow | -17.04 Cr | -0.58 Cr | 2.62 Cr | -1.20 Cr | — |
| Interest Received Cfi | 5.36 Cr | 5.47 Cr | 1.49 Cr | 5.04 Cr | — |
| Dividends Received Cfi | 0.09 Cr | 0.05 Cr | 0.04 Cr | 0.03 Cr | — |
| Net Investment Purchase And Sale | -2.78 Cr | -3.55 Cr | 3.18 Cr | -3.73 Cr | — |
| Sale Of Investment | 187.72 Cr | 147.15 Cr | 88.57 Cr | 126.28 Cr | — |
| Purchase Of Investment | -190.50 Cr | -150.71 Cr | -85.38 Cr | -130.01 Cr | — |
| Net PPE Purchase And Sale | -19.71 Cr | -2.55 Cr | -2.10 Cr | -2.55 Cr | — |
| Sale Of PPE | 0.00 | 0.00 | 4000.00 | 0.51 Cr | — |
| Purchase Of PPE | -19.71 Cr | -2.55 Cr | -2.10 Cr | -3.05 Cr | — |
| Operating Cash Flow | 27.91 Cr | 8.12 Cr | 17.05 Cr | 9.27 Cr | — |
| Taxes Refund Paid | -13.43 Cr | -8.26 Cr | -8.22 Cr | -7.56 Cr | — |
| Change In Working Capital | 0.49 Cr | -18.22 Cr | -6.05 Cr | -10.79 Cr | — |
| Change In Other Current Liabilities | 0.89 Cr | -0.91 Cr | -4.42 Cr | 1.72 Cr | — |
| Change In Other Current Assets | -1.41 Cr | -14.21 Cr | -0.61 Cr | -11.14 Cr | — |
| Change In Payable | 1.90 Cr | 0.16 Cr | -1.01 Cr | 2.52 Cr | — |
| Change In Inventory | -0.32 Cr | -0.22 Cr | 1.55 Cr | -2.31 Cr | — |
| Change In Receivables | -1.15 Cr | -3.69 Cr | -1.59 Cr | -1.05 Cr | — |
| Other Non Cash Items | -4.79 Cr | -3.83 Cr | -3.63 Cr | -3.92 Cr | — |
| Provisionand Write Offof Assets | 0.08 Cr | 1.29 Cr | 0.59 Cr | 0.08 Cr | — |
| Deferred Tax | 11.87 Cr | 9.11 Cr | 8.26 Cr | 7.57 Cr | — |
| Depreciation And Amortization | 2.73 Cr | 2.34 Cr | 2.26 Cr | 1.90 Cr | — |
| Depreciation | 2.73 Cr | 2.34 Cr | 2.11 Cr | 1.68 Cr | — |
| Gain Loss On Investment Securities | -0.94 Cr | -0.19 Cr | -0.05 Cr | -0.03 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -0.19 Cr | -0.12 Cr | -0.76 Cr | -0.24 Cr | — |
| Gain Loss On Sale Of PPE | 0.03 Cr | 0.02 Cr | 0.05 Cr | -0.03 Cr | — |
| Net Income From Continuing Operations | 32.06 Cr | 25.98 Cr | 24.61 Cr | 22.30 Cr | — |
| Repurchase Of Capital Stock | — | 0.00 | -14.52 Cr | 0.00 | — |
| Net Other Financing Charges | — | 1000.00 | -1000.00 | — | 0.14 Cr |
| Net Common Stock Issuance | — | 0.00 | -14.52 Cr | 0.00 | — |
| Common Stock Payments | — | 0.00 | -14.52 Cr | 0.00 | — |
| Amortization Cash Flow | — | 0.29 Cr | 0.15 Cr | 0.22 Cr | 0.40 Cr |
| Other Cash Adjustment Outside Changein Cash | — | — | — | -1000.00 | — |
| Net Other Investing Changes | — | — | — | -1000.00 | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Jenburkt Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.